Biochemical and Pharmacologic Inequivalence of Low Molecular Weight Heparins
- 1 June 1989
- journal article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 556 (1), 333-353
- https://doi.org/10.1111/j.1749-6632.1989.tb22515.x
Abstract
Click on the article title to read more.This publication has 34 references indexed in Scilit:
- Evaluation of Thrombin Activity by Immunoquantitation of Fibrinopeptide A GenerationSeminars in Thrombosis and Hemostasis, 1986
- Clinical Efficacy of Heparin Fractions: Issues and AnswersCRC Critical Reviews in Clinical Laboratory Sciences, 1986
- A Primate Model (Macaca Mulatta) to Study the Pharmacokinetics of Heparin and Its FractionsSeminars in Thrombosis and Hemostasis, 1985
- Usefulness of Fibrinopeptide A Generation Tests in Experimental and Clinical Studies with Low Molecular Weight Heparin FractionsSeminars in Thrombosis and Hemostasis, 1985
- Validity of Serine Protease Inhibition Tests in the Evaluation and Monitoring of the Effect of Heparin and Its FractionsSeminars in Thrombosis and Hemostasis, 1985
- Molecular Weight of Heparin Versus Biologic Activity Some Additional ConsiderationsSeminars in Thrombosis and Hemostasis, 1985
- From Heparin to Heparin Fractions and DerivativesSeminars in Thrombosis and Hemostasis, 1985
- Development of Fibrinopeptide A Generation Tests in the Evaluation and the Monitoring of the Action of Heparin and Its Low Molecular Weight FractionsSeminars in Thrombosis and Hemostasis, 1984
- Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activityBiochemical and Biophysical Research Communications, 1983
- Clinical Pharmacokinetics of HeparinClinical Pharmacokinetics, 1980